| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Arizona Cancer Center [D. S. A., R. T. D., J. G. E., K. S., M. J. X., Y-M. P., R. G., J. A. F., S. S., D. J. R., G. T. B.], and Department of Surgery, College of Medicine [J. A. W.], University of Arizona, Tucson, Arizona 85724; and Kaiser Center for Health Research, Portland, Oregon 97227-1098 [M. A.]
-2-(Difluoromethyl)-dl-ornithine
(DFMO), an irreversible inhibitor of ornithine decarboxylase,
has been shown to suppress skin carcinogenesis in murine models after
oral or topical administration. We designed a randomized,
placebo-controlled study using a topical hydrophilic ointment
formulation with or without 10% (w/w) DFMO. Forty-eight participants
with moderate-severe actinic keratoses (AKs) on their forearms
(i.e., at least 10 well-circumscribed lesions on the
lateral surface) completed a 1-month run-in on placebo ointment. Before
randomization, all lateral forearm AKs were circled, counted,
photographed, and skin biopsies were obtained for DFMO and polyamine
levels. Then participants were randomized to receive DFMO ointment on
the right versus the left forearm and placebo
hydrophilic ointment on the contralateral forearm twice daily for 6
months. DFMO was not detected in the blood of any subject, and there
were no systemic toxicities. None of a subsample of 17 placebo forearms
had measurable concentrations of DFMO, whereas 13 of the corresponding
DFMO-treated forearms had high DFMO skin levels. As compared with
placebo, the 6-month DFMO treatment caused a 23.5% reduction in the
number of AKs (P = 0.001) as well as significant
suppression of AK biopsy spermidine levels (26%; P = 0.04). Seven of the 48 (14.6%) participants experienced severe (2;
4.2%) or moderate (5; 10.4%) inflammatory reactions on their
DFMO-treated arms which required dosing modification. Topical DFMO for
6 months can reduce the number of AK lesions and skin spermidine
concentrations in high-risk participants and deserves additional study
as a skin cancer chemopreventive agent.
This article has been cited by other articles:
|
|
 |
|
  N. A. IGNATENKO, H. F. YERUSHALMI, R. PANDEY, K. L. KACHEL, D. E. STRINGER, L. J. MARTON, and E. W. GERNER Gene Expression Analysis of HCT116 Colon Tumor-derived Cells Treated with the Polyamine Analog PG-11047 Cancer Genomics Proteomics, May 1, 2009; 6(3): 161 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Foote, J. R. Ranger-Moore, J. G. Einspahr, K. Saboda, J. Kenyon, J. Warneke, R. C. Miller, R. Goldman, M.-J. Xu, D. J. Roe, et al. Chemoprevention of Human Actinic Keratoses by Topical DL-{alpha}-tocopherol Cancer Prevention Research, April 1, 2009; 2(4): 394 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Simoneau, E. W. Gerner, R. Nagle, A. Ziogas, S. Fujikawa-Brooks, H. Yerushalmi, T. E. Ahlering, R. Lieberman, C. E. McLaren, H. Anton-Culver, et al. The Effect of Difluoromethylornithine on Decreasing Prostate Size and Polyamines in Men: Results of a Year-Long Phase IIb Randomized Placebo-Controlled Chemoprevention Trial Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 292 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. L. Meyskens Jr. American Society of Preventive Oncology Distinguished Career Achievement Lecture 2006--Enjoy the Journey: The Long and Winding Road of Chemoprevention Agent Development. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2038 - 2041. [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Petros, G. F. Graminski, S. Robinson, M. R. Burns, N. Kisiel, R. F. Gesteland, J. F. Atkins, D. L. Kramer, M. T. Howard, and R. S. Weeks Polyamine Analogs with Xylene Rings Induce Antizyme Frameshifting, Reduce ODC Activity, and Deplete Cellular Polyamines J. Biochem., November 1, 2006; 140(5): 657 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Einspahr, M.-J. Xu, J. Warneke, K. Saboda, J. Ranger-Moore, P. Bozzo, L. Duckett, R. Goldman, P. Lin, J. Buckmeier, et al. Reproducibility and Expression of Skin Biomarkers in Sun-Damaged Skin and Actinic Keratoses Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1841 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-T. Vlastos, L. A. West, E. N. Atkinson, I. Boiko, A. Malpica, W. K. Hong, and M. Follen Results of a Phase II Double-Blinded Randomized Clinical Trial of Difluoromethylornithine for Cervical Intraepithelial Neoplasia Grades 2 to 3 Clin. Cancer Res., January 1, 2005; 11(1): 390 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Carpenter, K. G. Linden, C. E. McLaren, K.-T. Li, S. Arain, R. J. Barr, P. Hite, J. D. Sun, and F. L. Meyskens Jr. Nuclear Morphometry and Molecular Biomarkers of Actinic Keratosis, Sun-Damaged, and Nonexposed Skin Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 1996 - 2002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. Wattenberg, T. S. Wiedmann, and R. D. Estensen Chemoprevention of Cancer of the Upper Respiratory Tract of the Syrian Golden Hamster by Aerosol Administration of Difluoromethylornithine and 5-Fluorouracil Cancer Res., April 1, 2004; 64(7): 2347 - 2349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Y. Y. Fong, D. J. Feith, and A. E. Pegg Antizyme Overexpression in Transgenic Mice Reduces Cell Proliferation, Increases Apoptosis, and Reduces N-Nitrosomethylbenzylamine-induced Forestomach Carcinogenesis Cancer Res., July 15, 2003; 63(14): 3945 - 3954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Wheeler, K. J. Ness, T. D. Oberley, and A. K. Verma Inhibition of the Development of Metastatic Squamous Cell Carcinoma in Protein Kinase C {epsilon} Transgenic Mice by {alpha}-Difluoromethylornithine Accompanied by Marked Hair Follicle Degeneration and Hair Loss Cancer Res., June 15, 2003; 63(12): 3037 - 3042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Fischer, C. J. Conti, J. Viner, C.M. Aldaz, and R. A. Lubet Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice Carcinogenesis, May 1, 2003; 24(5): 945 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Managing solar keratoses DTB, May 1, 2002; 40(5): 33 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Einspahr, M. A. Nelson, K. Saboda, J. Warneke, G. T. Bowden, and D. S. Alberts Modulation of Biologic Endpoints by Topical Difluoromethylornithine (DFMO), in Subjects at High-Risk for Nonmelanoma Skin Cancer Clin. Cancer Res., January 1, 2002; 8(1): 149 - 155. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
